Loading...
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
BACKGROUND: Overexpression of ErbB2 receptor in breast cancer is associated with disease progression and poor prognosis. Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer, has proven to be effective; however, a relevant problem for clinical practice is that a high f...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2822937/ https://ncbi.nlm.nih.gov/pubmed/20051960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605499 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|